Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 68071-4442

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 68071-4442). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 4442 9

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (Venlafaxineercaps Figure 01)

This appears to be a table listing interactions between various drugs and their effects on the pharmacokinetics (PK) of venlafaxine. The listed drugs include ethanol, diazepam, cimetidine, ketoconazole, indinavir, metoprolol, imipramine, and lithium. The table provides recommendations for dosing adjustments and monitoring based on PK fold change and 90% CI values. It appears that caution should be exercised in patients with hypertension, the elderly, or hepatic dysfunction, and that some drug interactions may have unknown clinical significance.*

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (Venlafaxineercaps Figure 02)

This text appears to be a list of drugs and their interactions, as well as their recommended PKFold changes and clinical significance. It seems to caution against concomitant use of some of these drugs and the importance of monitoring blood pressure. There is also mention of certain drugs not requiring dose adjustments or having unknown clinical significance. However, due to inconsistencies in the formatting and missing information, some of the text is difficult to interpret.*

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (Venlafaxineercaps Figure 03)

This is a table that includes information on the effects of special populations (such as individuals with hepatic or renal impairment or CYP2D8 polymorphism) on the PK (pharmacokinetics) of the drug analyte venlafaxine. The table provides recommendations for dose adjustments based on the fold change and 90% CI (confidence interval) values. For example, for individuals with severe hepatic impairment or who are extensive metabolizers, the dose of venlafaxine should be reduced by 50% or more. However, in cases where there is no dose adjustment recommended, individualization of dosing may still be necessary.*

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (Venlafaxineercaps Figure 04)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.